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Abstract
Background: HCV infection frequently induces chronic liver diseases. The current standard treatment for chronic
hepatitis (CH) C combines pegylated interferon (IFN) and ribavirin, and is less than ideal due to undesirable effects.
MicroRNAs (miRNAs) are endogenous small non-coding RNAs that control gene expression by degrading or
suppressing the translation of target mRNAs. In this study we administered the standard combination treatment to
CHC patients. We then examined their miRNA expression profiles in order to identify the miRNAs that were
associated with each patient’s drug response.
Methods: 99 CHC patients with no anti-viral therapy history were enrolled. The expression level of 470 mature
miRNAs found their biopsy specimen, obtained prior to the combination therapy, were quantified using microarray
analysis. The miRNA expression pattern was classified based on the final virological response to the combination
therapy. Monte Carlo Cross Validation (MCCV) was used to validate the outcome of the prediction based on the
miRNA expression profile.
Results: We found that the expression level of 9 miRNAs were significantly different in the sustained virological
response (SVR) and non-responder (NR) groups. MCCV revealed an accuracy, sensitivity, and specificity of 70.5%,
76.5% and 63.3% in SVR and non-SVR and 70.0%, 67.5%, and 73.7% in relapse (R) and NR, respectively.
Conclusions: The hepatic miRNA expression pattern that exists in CHC patients before combination therapy is
associated with their therapeutic outcome. This information can be utilized as a novel biomarker to predict drug
response and can also be applied to developing novel anti-viral therapy for CHC patients.
Background
Hepatitis C virus (HCV) infection affects more than 3%
of the world population. HCV infection frequently
induces chronic liver diseases ranging from chronic
hepatitis (CH) C, to liver cirrhosis (LC) and hepatocellu-
lar carcinoma (HCC) [1]. The current standard treat-
ment for CHC combines pegylated interferon (Peg-IFN)
and ribavirin, and has been found to be effective in only
50% of HCV genotype 1b infection. Furthermore this
form of therapy is often accompanied by adverse effects;
therefore, there is a pressing need to develop alternative
strategies to treat CHC and to identify patients that will
not be responsive to treatment [2].
MicroRNAs (miRNAs) are endogenous small non-
coding RNAs that control gene expression by degrading
or suppressing the translation of target mRNAs [3,4].
There are currently 940 identifiable human miRNAs
(The miRBase Sequence Database – Release 15.0). These
miRNAs can recognize hundreds of target genes with
incomplete complementary over one third of human
genes appear to be conserved miRNA targets [5,6].
miRNA can associate not only several pathophysiologic
events but also cell proliferation and differentiation.
However, there are many miRNAs whose functions
are still unclear. Examples include miR-122 which is an
abundant liver-specific miRNA that is said to constitute
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The expression level of miR-122 was reportedly asso-
ciated with early response to IFN treatment, while
others like miR-26 have expression status that is asso-
ciated with HCC survival and response to adjuvant ther-
apy with IFN [8,9]. IFN beta (IFNb)o nt h eo t h e rh a n d ,
has been shown to rapidly modulate the expression of
numerous cellular miRNAs, and it has been demon-
strated that 8 IFNb-induced miRNAs have sequence-
predicted targets within the hepatitis C virus (HCV)
genomic RNA [10]. Finally several miRNAs have been
recognized as having target sites in the HCV genome
that inhibits viral replication [10-12].
To date, various parameters have been examined in an
attempt to confirm the effects of the IFN-related treatment
for CHC. In patients with chronic HCV genotype 1b infec-
tion, there is a substantial correlation between responses
to IFN and mutation in the interferon sensitivity determin-
ing region (ISDR) of the viral genome [13]. Substitutions
of amino acid in the HCV core region (aa 70 and aa 91)
were identified as predictors of early HCV-RNA negativity
and several virological responses, including sustained
response to standard combination therapy [14]. In order to
assess the drug response to combination therapy for CHC
using gene expression signatures, several researchers cata-
loged the IFN related gene expression profile from liver tis-
sue or peripheral blood mononuclear cells (PBMC) [15,16].
It was found that failed combination therapy was asso-
ciated with up-regulation of a specific set of IFN-respon-
sive genes in the liver before treatment [17]. Additional
reports have indicated that two SNPs near the gene IL28B
on chromosome 19 may also be associated with a patient’s
lack of response to combination therapy [18]. These
reports suggest that gene expression during the early phase
of anti-HCV therapy may elucidate important molecular
pathways for achieving virological response [19].
Our aim in this study was to identify gene related fac-
tors that contribute to poor treatment response to com-
bination therapy for CHC. In order to achieve this we
studied the miRNA expression profile of CHC patients
before treatment with CHC combination therapy and
tried to determine the miRNAs that were associated
with their drug response. Knowing patients’ expression
profile is expected to provide a clearer understanding of
how aberrant expression of miRNAs can contribute to
the development of chronic liver disease as well as aid
in the development of more effective and safer thera-
peutic strategies for CHC.
Methods
Patients and sample preparation
Ninety-nine CHC patients with HCV genotype 1b were
enrolled (Table 1). Patients with autoimmune hepatitis,
or alcohol-induced liver injury, or hepatitis B virus-asso-
ciated antigen/antibody or anti-human immunodefi-
ciency virus antibody were excluded. There were no
patients who received IFN therapy or immunomodula-
tory therapy before enrollment in the study. Serum
HCV RNA was quantified before IFN treatment using
Amplicor-HCV Monitor Assay (Roche Molecular Diag-
nostics Co., Tokyo, Japan). Liver biopsy specimen was
collected from each patient up to one week prior to
administering combination therapy. Histological grading
and staging of liver biopsy specimens from the CHC
patients were performed according to the Metavir classi-
fication system. Pretreatment blood tests were con-
ducted to determine each patient’s level of aspartate
aminotransferase, alanine aminotransferase, total biliru-
bin, alkaline phosphatase, gamma-glutamyl transpepti-
dase, white blood cell (WBC), platelets, and hemoglobin.
Written informed consent was obtained from all of the
patients or their guardians and provided to the Ethics
Committee of the Graduate School of Kyoto University,
who approved the conduct of this study in accordance
with the Helsinki Declaration.
Table 1 Clinical characteristics of patients
Characteristics SVR
(n = 46)
R
(n = 28)
NR
(n = 25)
p-value
Age (years) 57.0 ± 9.8 61.2 ± 8.3 60.6 ± 7.6 0.09†
Male (%) 28 (61%) 11 (39%) 9 (36%) 0.08§
Weight (kg) 59.5 ± 9.0 56.6 ± 9.9 56.0 ± 7.7 0.13†
HCV RNA (×10
6
copies/ml)
1.90 ± 1.95 1.83 ± 1.04 1.58 ± 0.93 0.62†
Fibrosis stage
F 0 1 1 1 0.50§
F 1 29 16 10
F2 1 0 7 6
F3 6 4 7
F4 0 0 1
WBC(×10
3/mm
3) 5.31 ± 1.59 5.18 ± 1.24 4.71 ± 1.15 0.29†
Hemoglobin (g/dl) 14.2 ± 1.26 13.6 ± 1.35 13.5 ± 1.13 0.022†
Platelet (×10
4/mm
3) 16.7 ± 5.0 16.4 ± 4.0 15.2 ± 6.1 0.25†
AST (IU/L) 54.8 ± 48.1 46.6 ± 29.3 57.0 ± 28.5 0.17†
ALT (IU/L) 74.5 ± 87.8 47.9 ± 28.6 67.6 ± 43.2 0.15†
gGTP (IU/L) 56.0 ± 69.4 38.5 ± 28.9 74.3 ± 59.0 0.025†
ALP (IU/L) 248 ± 71.5 245 ± 75.7 323 ± 151 0.038†
Total Bilirubin (mg/dl) 0.67 ± 0.22 0.72 ± 0.30 0.68 ± 0.19 0.95†
Albumin (g/dl) 4.21 ± 0.31 4.13 ± 0.27 4.01 ± 0.48 0.14†
Abbreviations. SVR, sustained virological response; R, relapse; NR, non
responder; Differences in clinical characteristics among three groups were
tested using †Kruskal-Wallis test, or §Fisher’s exact test. AST, aspartate
aminotransferase; ALT, alanine aminotransferase; WBC, white blood cell; ALP,
alkaline phosphatase; gGTP, gamma-glutamyl transpeptidase.
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Page 2 of 13Treatment protocol and definitions
All enrolled patients were treated with pegylated IFNa-
2b (Schering-Plough Corporation, Kenilworth, NJ, USA)
and ribavirin (Schering-Plough) for 48 weeks (Figure 1).
Pegylated IFN was administered at a dose of 1.5 mg kg/
week at the starting point. Ribavirin was administered
following the dose recommended by the manufacturer.
Definitions of drug response to therapy
Drug response was defined according to how much HCV
RNA had decreased in each patient’s serum. After four
weeks of drug administration (rapid response phase) the
patients were classified into the following two groups
after four weeks of drug administration: (i) rapid virologi-
cal responder (RVR): a patient whose serum was negative
for serum HCV RNA at four weeks, and (ii) non-RVR: a
patient who was not classified as RVR.
The patients were classified into the following three
groups after 12 weeks of drug administration (early
response phase): (i) complete early virological responder
(cEVR): a patient who was negative for serum HCV
RNA at 12 weeks; (ii) partial EVR: a patient whose
serum HCV RNA was reduced by 2-log or more of the
HCV RNA before drug administration at 12 weeks, but
who was not negative for serum HCV RNA; and (iii)
non-EVR: a patient who was not classified as either
cEVR or pEVR.
The patients were classified into the following three
groups at the time of post-treatment at 24 weeks (final
response): (i) sustained virological responder (SVR): a
patient who was negative for serum HCV RNA during
the six months following completion of the combination
therapy; (ii) relapse (R): a patient whose serum HCV
RNA was negative by the end of the combination ther-
apy but reappeared after completion of the combination
therapy; and (iii) virological non-responder (NR): a
patient who was positive for serum HCV RNA during
the entire course of the combination treatment.
RNA extraction
Liver biopsy specimens were stored in RNA later
(Ambion, Austin, TX, USA) at -80°C until RNA
Figure 1 Study design and time-line response to combination therapy. The time-course of liver biopsy, microarray analysis, therapeutic
period, observation period after combination therapy, and drug response judgment time (4W, 12W, 72W) is shown. Each therapeutic result
(rapid, early, and final response) and the number of patients transitioning into each group are shown. RVR, cEVR, pEVR, SVR, R, and NR are
denoted as rapid virological response, complete early virological response, partial EVR, sustained virological response, relapse, and non responder,
respectively.
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miRNA Isolation kit (Ambion) according to the manu-
facturer’s instruction.
miRNA microarray
miRNA microarrays were manufactured by using Agilent
Technologies (Santa Clara, CA, USA). Total RNA (100
ng) were labeled and hybridized using a Human micro-
RNA Microarray kit (Agilent Technologies) according to
the manufacturer’s protocol (Protocol for use with Agi-
lent microRNA microarrays Version 1.5). Hybridization
signals were detected using the DNA microarray scanner
G2505B (Agilent Technologies), and all scanned images
were analyzed using Agilent feature extraction software
(v9.5.3.1). Data were analyzed using GeneSpring GX 7.3.1
software (Agilent Technologies) and normalized as fol-
lows: (i) values below 0.01 were set to 0.01. (ii) each mea-
surement was divided by the 75th percentile of all
measurements to compare one-color expression profiles.
The data presented in this manuscript have been depos-
ited in NCBI’s Gene Expression Omnibus and are acces-
sible through GEO Series accession number GSE16922:
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=xlm
bxyyumcwkeba&acc=GSE16922
Real-time qPCR for miRNA quantification
To detect the expression level of miRNA by real-time
qPCR, TaqMan® microRNA assay (Applied Biosystems)
was used to quantify the relative expression levels of
miR-18a (assay ID, 002422), miR-27b (assay ID, 000409),
miR-422b (assay ID, 000575), miR-143 (assay ID,
000466), miR-145 (assay ID, 000467), miR-34b (assay ID,
000427), miR-378 (assay ID, 000567) and U18 (assay ID,
001204) which was used as an internal control. cDNA
was synthesized by Taqman miRNA RT Kit (Applied Bio-
systems). Total RNA (10 ng) in 5 ul of nuclease free
water was added to 3 ul of 5× RT primer, 10× 1.5 ul of
reverse transcriptase buffer, 0.15 ul of 100 mM dNTP,
0.19 ul of RNase inhibitor, 4.16 ul of nuclease free water,
and 50 U of reverse transcriptase in a total volume of 15
ul. The reaction was performed for 30 min at 16°C, 30
min at 42°C, and five min at 85°C. All RT reactions were
run in triplicate. Chromo 4 detector (BIO-RAD, Her-
cules, CA, USA) was used to detect miRNA expression.
Method of predicting prognosis
Monte Carlo Cross Validation (MCCV) was used to
identify a set of prognostic miRNAs and to assess and
predict drug response [20,21]. We chose MCCV to
make up for relatively small number of patients. The 99
enrolled patients were repeatedly and randomly divided
100 times into training sets (TSs; size n = 10, 20, ..., 90)
and a corresponding validation set (VS; size = 99-n).
The percentile-normalized measures for miRNA
expression were compared between the 2 TS patient
groups of SVR and non-SVR (R and NR) by computing
absolute values of the difference for each of the 172 miR-
NAs that were higher than 10. A prognosis signature was
defined in terms of the expression measures of the miR-
NAs with the largest absolute differences. A 35-miRNA
prognosis predictor (PP) was established for TS patients
and its performance was assessed on VS patients. A PP
was computed by applying diagonal linear discriminant
analysis to the 35-miRNA PP of the TS patients (Table 2
and 3). The PP was applied to predict the prognoses of
the VS patients. The predicted and actual prognoses
(SVR or non-SVR) of the VS patients were compared to
obtain the following three measures of prognosis predic-
tion performance: (1) accuracy (proportion of correctly
predicted prognoses), (2) sensitivity (proportion of cor-
rectly predicted non-SVR) and (3) specificity (proportion
of correctly predicted SVR). 53 patients (N and NR) were
also repeatedly and randomly divided 100 times into
training sets (TSs; size n = 6, 12, ...42) and corresponding
validation set (VS; size = 53-n). Perl programs of our own
writing performed all analytical processes.
Cell lines and miRNA transfection
HEK293 cells were maintained in D-MEM (Invitrogen,
Carlsbad, CA, USA) with 10% fetal bovine serum, plated
in 60 mm diameter dishes and cultured to 70% conflu-
ence. 293 cells were plated in 6-well plates the day
before transfection and grown to 70% confluence. Cells
were transfected with 50 pmol of Silencer® negative con-
trol siRNA (Ambion) or double-stranded mature
miRNA (ds miRNA) or 2’-O-methylated antisense oligo-
nucleotide against the miRNA of interest (ASO miRNA)
(Hokkaido System Science, Sapporo, Japan) using lipo-
fectamine RNAiMAX (Invitrogen). Cells were harvested
2 days after transfection.
Real-time qPCR for mRNA quanification
cDNA was synthesized using the Transcriptor High
Fiderity cDNA synthesis Kit (Roche, Basel, Switzerland).
Total RNA (2 μg) in 10.4 μlo fn u c l e a s ef r e ew a t e rw a s
added to 1 μl of 50 mM random hexamer. The denatur-
ing reaction was performed for 10 min at 65°C. The
denatured RNA mixture was added to 4 μl of 5× reverse
transcriptase buffer, 2 μl of 10 mM dNTP, 0.5 μlo f4 0U /
μlR N a s ei n h i b i t o r ,a n d1 . 1μl of reverse transcriptase
(FastStart Universal SYBR Green Master (Roche) in a
total volume of 20 μl. The reaction ran for 30 min at 50°
C (cDNA synthesis), and five min at 85°C (enzyme dena-
turation). All reactions were run in triplicate. Chromo
4 detector (BIO-RAD, Hercules, CA, USA) was used
to detect mRNA expression. The primer sequences are
as follows; BCL2 s; 5’-gttgctttacgtggcctgtt-3’,a s ;5 ’-
ggaggtctggcttcatacca-3’, RARA s; 5’-cataccctgccataccaacc-
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ggactgatgcc-3’,a s ;5 ’-gcttttgggcagtggttaag-3’,a n db-actin
s; 5’-ccactggcatcgtgatggac-3’,a s ;5 ’-tcattgccaatggtgat-
gacct-3’. Assays were performed in triplicate, and the
expression levels of target genes were normalized to the
expression of the b-actin gene, as quantified using real-
time qPCR as internal controls.
Statistical analysis
Data were statistically analyzed using the Student’s t-test
and differences in clinical characteristics among 3 groups
were tested using the Kruskal-Wallis test, or Fisher’s
exact test. Data from microarray were also statically
analyzed using Welch’s test and Benjamini-Hochberg
correction for multiple hypotheses testing.
Results
A microarray platform was used to determine miRNA
expression of 470 miRNAs in 99 fresh-frozen CHC liver
tissues.
miRNAs which related to the final response of
combination therapy
Unique miRNA expression patterns were established
according to the final virological response (SVR, R, and
NR) to the combination therapy (Figure 1). To isolate
Table 2 List of the 35 miRNAs used to classify patients into SVR and non-SVR groups using Monte Carlo Cross
Validation (MCCV)
Gene name fold change (SVR/non SVR) T-test Selection by MCCV
Rank appearance frequency in
this classification (%)
appearance number of times
hsa-miR-122a 1.32 6.67E-02 1 98.78 889
hsa-miR-21 1.19 3.62E-01 2 94.67 852
hsa-miR-22 1.23 7.80E-02 3 93.22 839
hsa-let-7a 1.14 3.57E-01 4 92.33 831
hsa-miR-23b 1.41 1.72E-02 5 91.44 823
hsa-miR-26a 1.32 7.45E-02 6 90.78 817
hsa-let-7f 1.15 4.04E-01 7 88.67 798
hsa-miR-142-3p 1.39 1.45E-01 8 87.33 786
hsa-miR-494 2.18 5.85E-03 9 82.00 738
hsa-miR-194 1.22 1.70E-01 10 80.78 727
hsa-let-7b 1.11 3.59E-01 11 80.22 722
hsa-miR-148a 1.25 2.28E-01 12 79.67 717
hsa-miR-29a 1.16 2.73E-01 13 77.78 700
hsa-miR-125b 1.20 2.37E-01 14 73.11 658
hsa-miR-192 1.09 4.89E-01 15 69.67 627
hsa-miR-24 1.25 8.31E-02 16 68.89 620
hsa-miR-768-3p 1.19 1.78E-01 17 68.78 619
hsa-miR-126 1.07 6.75E-01 18 49.56 446
hsa-miR-19b 1.15 2.98E-01 19 48.89 440
hsa-miR-370 2.00 1.44E-02 20 39.00 351
hsa-miR-29c 1.26 1.37E-01 21 38.89 350
hsa-miR-16 1.24 2.08E-01 22 37.11 334
hsa-miR-145 1.01 9.25E-01 23 34.89 314
hsa-let-7c 1.21 1.41E-01 24 33.22 299
hsa-miR-215 1.20 3.65E-01 25 27.67 249
hsa-let-7g 1.16 3.64E-01 26 27.44 247
hsa-miR-451 1.13 6.94E-01 27 23.11 208
hsa-miR-26b 1.30 2.26E-01 28 22.22 200
hsa-miR-92 1.12 3.44E-01 29 21.11 190
hsa-miR-29b 1.19 2.62E-01 30 19.44 175
hsa-miR-107 1.21 1.58E-01 31 18.78 169
hsa-miR-27b 1.40 2.32E-02 32 18.11 163
hsa-miR-638 1.32 5.57E-02 33 16.89 152
hsa-miR-199a* 1.12 5.92E-01 34 16.78 151
hsa-miR-193b 1.25 7.24E-02 35 16.67 150
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response to the combination therapy, we chose miRNAs
which had ≥ 1.25 fold difference in the mean values of
the gene expression level between at least two groups
(p < 0.05). Unsupervised hierarchical clustering based
on all the miRNAs spotted on the chip, revealed a
marked, very distinct separation according to the
patients’ final response of the CHC liver tissue to the
Peg-IFN and ribavirin combination therapy (Figure 2).
The result was that the expression level of 3 miRNAs
(miR-27b, miR-378, miR-422b) in SVR was significantly
higher than that in NR, whereas the expression level of
5 miRNAs (miR-34b, miR-145, miR-143, miR-652, and
miR-18a) in SVR was significantly lower than that in
NR. Without FDR correction, the expression level of
miR-122 in NR was lower than that in SVR. The expres-
sion level of 2 miRNAs in SVR was significantly higher
than that in R, whereas the expression level of 10 miR-
N A si nS V Rw a ss i g n i f i c a n t l yl o w e rt h a ni nt h a ti nR .
Additionally, the expression level of miR-148a in R was
significantly higher than that in NR. There was no sig-
nificant difference in the expression level of miR-122 in
NR and R (Table 4).
Validation of the microarray result by real-time qPCR
The three miRNAs (miR-18a, miR-27b, and miR-422b)
with the smallest difference of fold change between NR
and SVR groups and four miRNA (miR-143, miR-145,
Table 3 List of the miRNAs used to classify patients into R and NR groups
Gene name fold change (R/NR) T-test Selection by MCCV
Rank appearance frequency in this classification (%) appearance number of times
hsa-miR-122a 1.50 6.70E-02 1 98.57 690
hsa-miR-21 1.13 5.43E-01 2 89.86 629
hsa-let-7a 1.15 4.23E-01 3 88.71 621
hsa-let-7f 1.24 3.01E-01 4 87.43 612
hsa-miR-148a 1.70 4.51E-02 5 82.71 579
hsa-miR-192 1.24 1.93E-01 6 81.71 572
hsa-miR-126 1.21 3.19E-01 7 74.14 519
hsa-miR-22 1.04 7.88E-01 8 68.43 479
hsa-miR-194 1.20 3.63E-01 9 64.29 450
hsa-miR-23b 1.30 2.06E-01 10 62.00 434
hsa-miR-125b 1.23 2.88E-01 11 61.86 433
hsa-miR-494 0.45 8.17E-02 12 61.14 428
hsa-miR-19b 1.17 3.86E-01 13 61.14 428
hsa-miR-29a 1.11 5.44E-01 14 59.86 419
hsa-miR-26a 1.13 5.38E-01 15 58.43 409
hsa-let-7b 1.01 9.37E-01 16 56.86 398
hsa-miR-142-3p 1.15 5.54E-01 17 52.71 369
hsa-miR-215 1.28 3.93E-01 18 52.00 364
hsa-miR-101 1.31 1.26E-01 19 49.00 343
hsa-miR-451 1.35 5.25E-01 20 48.14 337
hsa-miR-145 0.99 9.76E-01 21 47.14 330
hsa-let-7g 1.15 4.84E-01 22 44.00 308
hsa-miR-29c 1.23 2.94E-01 23 43.71 306
hsa-miR-26b 1.37 2.85E-01 24 43.14 302
hsa-miR-768-3p 1.00 9.91E-01 25 36.29 254
hsa-let-7c 1.16 3.76E-01 26 36.14 253
hsa-miR-370 0.43 7.36E-02 27 35.57 249
hsa-miR-92 1.07 6.65E-01 28 34.14 239
hsa-miR-16 1.11 6.18E-01 29 26.71 187
hsa-miR-29b 1.14 5.19E-01 30 25.71 180
hsa-miR-27b 1.40 1.15E-01 31 25.71 180
hsa-miR-24 1.08 6.56E-01 32 20.57 144
hsa-miR-107 1.00 9.81E-01 33 19.57 137
hsa-miR-143 0.95 7.99E-01 34 18.43 129
hsa-miR-214 0.85 3.61E-01 35 17.86 125
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change between NR and SVR groups were chosen to con-
firm the microarray results using stem-loop based real-
time qPCR. The result of real-time qPCR corresponded
to the result from the microarray analysis (Figure 3).
miRNAs which related to the 4 week (rapid response
phase) response to combination therapy
The miRNA expression profile was established accord-
ing to the rapid phase response to the combination ther-
apy by week 4 (Table 5). Our results showed that the
expression level of 5 miRNAs in non-RVR was signifi-
cantly higher than that in RVR. Prior results have
revealed that a patient who achieves RVR as a result of
the combination therapy has a high possibility of achiev-
ing SVR [22,23]. Our research supports this finding:
nine out of 99 patients achieved RVR. All nine cases
shifted to cEVR by week 12, and 8 shifted to SVR at the
final response. The 90 cases in non-RVR shifted to 44
cases in cEVR, 19 in pEVR, and 27 in non-EVR and at
the final response shifted to 38 cases in SVR, 27 in R,
and 25 in NR (Table 6 and Figure 1).
miRNAs which related to the 12 week (early response
phase) response to combination therapy
Establishing the miRNA expression profile of patients
according to their 12 week (early response) of CHC
liver specimen to the combination therapy after 12
weeks, showed that the expression level of miR-23b and
miR-422b in cEVR was higher than that in non-EVR,
and the expression level of miR-34b in cEVR lower than
that in non-EVR (Table 5). There were no miRNAs with
expression level that differed significantly between cEVR
and pEVR, and non-EVR and pEVR. The drug response
at 12 weeks appeared to be a predictive factor of the
final drug response. The 53 cases in cEVR at week 12
shifted to 41 cases in SVR and 12 in R at the final
response. 27 cases in pEVR at week 12, shifted to 5 in
SVR, 15 in R, and 7 in NR and 19 in non-EVR shifted
to 1 in R and 18 in NR (Table 6 and Figure 1).
Predicting the final outcome before drug administration
using MCCV
Before initial drug administration, we attempted to
simulate the clinical outcome of the combination
Figure 2 Clustering of CHC patients according to their final response to Peg-IFN and ribavirin combination therapy.H e a t m a pu s i n g
miRNA differently expressed among SVR, R, and NR is shown (A: classification between NR and SVR, B: classification between NR and R, and C:
classification between R and SVR, respectively). Vertical bars represent the miRNA genes and the horizontal bars represent the samples. Green
bars reflect downregulated genes and red bars upregulated genes.
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Page 7 of 13Table 4 Extracted miRNA related to the final outcome of combination therapy
Gene Name Fold Change (NR/SVR) p-value with FDR correction p-value without correction
hsa-miR-34b* 1.50 3.53E-02 6.95E-05
hsa-miR-145 1.35 3.55E-02 5.50E-05
hsa-miR-143 1.31 4.65E-02 6.46E-04
hsa-miR-652 1.28 4.33E-02 3.43E-04
hsa-miR-18a 1.22 4.33E-02 2.02E-05
hsa-miR-27b 0.78 4.33E-02 3.97E-05
hsa-miR-422b* 0.71 4.33E-02 1.44E-04
hsa-miR-378 0.70 4.86E-02 1.38E-03
hsa-miR-122 0.72 > 5.00E-02 2.59E-04
Gene Name Fold Change (NR/R) p-value with FDR correction p-value without correction
hsa-miR-148a 0.59 1.60E-02 8.99E-04
has-miR-122 0.72 > 5.00E-02 6.23E-04
Gene Name Fold Change (R/SVR) P-value p-value without correction
hsa-let-7a 1.15 3.93E-02 1.94E-03
hsa-let-7f 1.24 1.04E-02 3.60E-03
hsa-let-7g 1.17 1.93E-02 1.82E-02
hsa-miR-100 1.23 1.93E-02 9.23E-04
hsa-miR-10a 1.37 1.26E-02 2.40E-03
hsa-miR-126 1.36 1.04E-02 1.50E-03
hsa-miR-21 1.30 4.78E-02 3.45E-02
hsa-miR-335 2.00 2.83E-02 3.50E-02
hsa-miR-370 0.36 1.38E-02 2.96E-03
hsa-miR-494 0.37 3.93E-02 1.97E-03
hsa-miR-590 1.26 3.93E-02 5.59E-03
hsa-miR-98 1.22 1.38E-02 6.64E-03
Asterisk was denoted the common miRNAs appeared whose expression level between NR and SVR, and nonEVR and cEVR.
Figure 3 Real-time qPCR validation of the seven miRNAs. Each column represents the relative amount of miRNAs normalized to expression
level of U18. The data shown were means+SD of three independent experiments. Asterisk indicates a significant difference of p < 0.05 (*) or
p < 0.01 (**).
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Page 8 of 13therapy before drug administration by using MCCV. We
first extracted the SVR and non-SVR groups from all of
the patients, and then the R and NR groups were pre-
dicted afterwards. MCCV simulation showed that the
accuracy, specificity, and sensitivity of the liver specimen
classified as SVR or non-SVR was up to 70.5%, 63.3%,
and 76.8%, respectively (TSs = 80). On the other hand,
the accuracy, specificity, and sensitivity of the liver spe-
cimen classified as R or NR was 70.0%, 73.7%, and
67.5%, respectively (TSs = 42)(Figure 4). Fold change of
their normalized expression level, P value, and number
of selection by MCCV in the 35 informative miRNAs
that were identified based on the all patients are shown
in Table 2 and 3.
miRNAs related to the final drug response can regulate
the immune related genes
In order to clarify the biological links between miR-
NAs and IFN responses, we examined whether the
expression of immune-related hypothetical miRNAs
target genes (additional file 1) could be controlled by
miRNAs which were related to the final drug
response. We observed the changes in expression level
of B-cell CLL/lymphoma 2 (BCL2), retinoic acid
receptor, alpha (RARA), and SMAD family member 2
(SMAD2) by real-time qRT-PCR as the expression
level of miRNAs (miR-143, miR-27b, and miR-18a)
was modified, respectively, in HEK293 cells. The
expression level of the hypothetical targets examined
was down-regulated by over-expression of the corre-
sponding miRNA and the corresponding antisense oli-
gonucleotide (ASO) inhibited the function of miRNA
(additional file 2).
Discussion
Our large and comprehensive screening revealed that
hepatic miRNA expression can be associated with a
patient’s drug response. There are several reports that
miRNAs are closely related to innate immunity, and in
this study, we found that several miRNAs had the
potential to recognize immuno-related genes as target
candidates [24-26]. For example, the following hypothe-
tical candidate genes of miR-378, miR-18a, miR-27b,
miR-34b, and miR-145 each identified as target genes,
Interferon Response Factor (IRF) 1, IRF2, IRF4, IRF6,
and IRF7, respectively (additional file 1). Past reports
show that miR-422b was related to the B cell differentia-
tion [27]. When an immuno-reaction induces aberrant
expression of miRNA, the expression level of miR-34b
significantly decreased in H69 cells following IFN-g sti-
mulation [28]. Bcl-6 positively directs follicular helper T
cell differentiation, through combined repression of
miR-18a and miR-27b and transcription factors [29].
In our study, there was significant difference in the
fold change of the expression level of miRNA based on
the drug response, however, the absolute value of the
fold change was not so significant (Table 4). Usually one
miRNA can regulate many genes including immuno-
related gene (additional file 1), and these genes in turn
can synergistically affect immune activity. In our preli-
minary study (additional file 2) BCL-2, RARA, and
SMAD2 can be regulated by miR-143, miR-18a, and
miR-27b, respectively. Considering that the expression
level of several miRNAs changed these minute changes
taken together can have a significant impact on a
patient’s drug-response and innate immunity.
Aberrant expression of miRNA can modify the repli-
cation of HCV. According to Vita algorithm, several
miRNAs, related to drug response, can recognize HCV
genotype 1b sequence as a target (additional file 3) [30].
For example, miR-199a* is able to target the HCV gen-
ome and inhibit viral replication [12]. IFN has the ability
to modulate expression of certain miRNAs that may
either target the HCV RNA genome (miR-196 or miR-
Table 5 List of the miRNA related to the rapid or early outcome of combination therapy
Gene Name Fold Change (non RVR/RVR) p-value p-value without correction
hsa-let-7c 1.17 2.01E-02 8.31E-03
hsa-let-7d 1.13 3.50E-02 5.63E-02
hsa-miR-139 1.29 3.35E-02 2.70E-02
hsa-miR-324-5p 1.14 1.64E-02 3.24E-02
hsa-miR-768-5p 1.34 4.57E-02 1.29E-02
Gene Name Fold Change (non EVR/cEVR) p-value p-value without correction
hsa-miR-34b* 1.51 3.30E-02 1.69E-04
hsa-miR-23b 0.74 2.69E-02 8.91E-05
hsa-miR-422b* 0.67 2.40E-02 1.34E-04
hsa-miR-122 0.74 > 5.00E-02 3.07E-03
Asterisk was denoted the common miRNAs appeared whose expression level between NR and SVR, and nonEVR and cEVR.
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Page 9 of 13Table 6 Patients’ periodical drug response changes
code No. 4W
treatment
(rapid
response)
12W
treatment
(early
response)
48W treatment
+24W observation
(final outcome)
code No 4W
treatment
(rapid
response)
12W
treatment
(early
response)
48W treatment
+24W observation
(final outcome)
OCH-105 non RVR non EVR NR OCH-103 RVR cEVR SVR
OCH-111 non RVR pEVR NR OCH-104 non RVR cEVR SVR
OCH-118 non RVR non EVR NR OCH-107 non RVR cEVR SVR
OCH-119 non RVR non EVR NR OCH-108 non RVR cEVR SVR
OCH-122 non RVR pEVR NR OCH-109 non RVR cEVR SVR
OCH-123 non RVR non EVR NR OCH-110 non RVR cEVR SVR
OCH-126 non RVR non EVR NR OCH-112 non RVR pEVR SVR
OCH-127 non RVR non EVR NR OCH-114 RVR cEVR SVR
OCH-132 non RVR pEVR NR OCH-116 non RVR cEVR SVR
OCH-137 non RVR non EVR NR OCH-121 non RVR pEVR SVR
OCH-140 non RVR pEVR NR OCH-124 non RVR cEVR SVR
OCH-142 non RVR non EVR NR OCH-130 non RVR cEVR SVR
OCH-144 non RVR pEVR NR OCH-131 non RVR cEVR SVR
OCH-145 non RVR non EVR NR OCH-136 non RVR cEVR SVR
OCH-192 non RVR non EVR NR OCH-138 non RVR cEVR SVR
OCH-204 non RVR non EVR NR OCH-139 non RVR cEVR SVR
OCH-205 non RVR non EVR NR OCH-143 non RVR cEVR SVR
OCH-206 non RVR non EVR NR OCH-150 non RVR cEVR SVR
OCH-207 non RVR non EVR NR OCH-153 non RVR cEVR SVR
OCH-208 non RVR non EVR NR OCH-154 non RVR cEVR SVR
OCH-209 non RVR pEVR NR OCH-155 non RVR cEVR SVR
OCH-210 non RVR non EVR NR OCH-156 non RVR cEVR SVR
OCH-211 non RVR non EVR NR OCH-157 non RVR pEVR SVR
OCH-223 non RVR non EVR NR OCH-158 non RVR pEVR SVR
OCH-242 non RVR pEVR NR OCH-160 non RVR cEVR SVR
OCH-101 non RVR cEVR R OCH-186 non RVR cEVR SVR
OCH-102 RVR cEVR R OCH-187 non RVR cEVR SVR
OCH-106 non RVR non EVR R OCH-189 non RVR pEVR SVR
OCH-113 non RVR pEVR R OCH-190 non RVR cEVR SVR
OCH-115 non RVR cEVR R OCH-191 RVR cEVR SVR
OCH-117 non RVR cEVR R OCH-194 non RVR cEVR SVR
OCH-120 non RVR pEVR R OCH-195 non RVR cEVR SVR
OCH-125 non RVR pEVR R OCH-222 non RVR cEVR SVR
OCH-128 non RVR pEVR R OCH-228 non RVR cEVR SVR
OCH-129 non RVR pEVR R OCH-229 RVR cEVR SVR
OCH-133 non RVR pEVR R OCH-230 non RVR cEVR SVR
OCH-134 non RVR pEVR R OCH-231 non RVR cEVR SVR
OCH-135 non RVR cEVR R OCH-232 non RVR cEVR SVR
OCH-141 non RVR cEVR R OCH-233 non RVR cEVR SVR
OCH-151 non RVR pEVR R OCH-234 RVR cEVR SVR
OCH-152 non RVR pEVR R OCH-236 non RVR cEVR SVR
OCH-159 non RVR pEVR R OCH-237 non RVR cEVR SVR
OCH-188 non RVR cEVR R OCH-238 non RVR cEVR SVR
OCH-213 non RVR cEVR R OCH-240 RVR cEVR SVR
OCH-214 non RVR pEVR R OCH-241 RVR cEVR SVR
OCH-215 non RVR pEVR R OCH-243 RVR cEVR SVR
OCH-216 non RVR cEVR R
OCH-217 non RVR pEVR R
OCH-218 non RVR cEVR R
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Page 10 of 13448) or markedly enhance its replication (miR-122)
[10,11]. The low expression level of miR-122 in the sub-
jects shown in the NR group is in accordance with our
results, however, after miRNA expression profile with
FDR correction, the expression level of miR-122 was not
significantly different between SVR and NR groups [8].
One reason why this difference is that their study com-
prised of patients infected with HCV genotype from 1
to 4 while this study consisted of HCV genotype 1b
patients only.
The expression pattern of mRNA in HCV infected
liver tissue is different from that of healthy tissue [15].
The expression pattern of the IFN-related genes in liver
tissue before administering of IFN therapy, also differs
according to the drug response [15,19]. The amount of
plasmacytoid dendritic cell (pDC), which are the most
potent secretors of antiviral Type-I IFN, has been shown
to decrease in the peripheral blood of patients, however,
pDC tend to become trapped in the liver tissue if HCV
infection is present [31,32]. Taken together, it is possible
that the variation in the miRNA expression pattern
according to the drug response existed even before
therapy.
Previously, large randomized controlled trials of IFN
therapy for CHC, identified at pre-treatment stage sev-
eral possible factors which are associated with the final
virological response. These factors include: genotype,
amount of HCV RNA in peripheral blood, degree of
fibrosis, age, body weight, ethnicity, and steatosis [33].
Viral genome mutation in the ISDR region and the
Table 6: Patients?’? periodical drug response changes (Continued)
OCH-219 non RVR pEVR R
OCH-220 non RVR cEVR R
OCH-221 non RVR pEVR R
OCH-239 non RVR cEVR R
Figure 4 Method for predicting the clinical outcome using MCCV. Prediction performance of signatures from 35 miRNAs (Table 2 and 3).
Left: Mean accuracy, specificity, and sensitivity (% in vertical axis) as a function of the training set size were determined for the 100 random
splits of patients (non-SVR (NR+R) vs. SVR). Right: prediction performance of the training set size was determined by performing 48 random splits
of patients (NR vs. R). A. Prediction performance (mean accuracy, specificity, and sensitivity) and number of miRNAs which was used for the
prediction are also shown in each training set (TS) and validation set (VS).
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Page 11 of 13substitutions of amino acid in the HCV core region also
served as predictors of early, as well as end-of treatment
response [13,14]. The miRNA expression obtained from
the therapeutic response, can be applied to the predic-
tion of drug response. The advantages of using miRNA
for the microarray analysis include the following; (i) It
was relatively easy to analyze because fewer probes were
installed compared with the usual cDNA array. (ii) The
change in each manifestation of a miRNA was low, in
fact, in most miRNA, standard deviation was twice or
less in average value (data not shown). The expression
levels of miR-34b and 422b in the early response phase
and final responses to treatment were consistently and
significantly high and low in non-responders, respec-
tively. Therefore these two miRNAs may be useful mar-
kers for early-to-final drug response to the IFN
treatment.
Further studies are indeed needed to clarify the con-
nection between miRNA expression and patient
response to CHC combination therapy. Because infor-
mation on miRNA is regularly being updated, we are
planning to performed more analysis using the latest
microarray and a larger sample in the future. However,
in the meantime, as we have shown in Figure 4, the big-
ger the size of the training set, the higher the prediction
performance that is achieved. This combined with the
results of our Monte Carlo cross validation provided a
strong based to verify the concepts in this report. We
believe that our results have three advantages (i) the
prediction methods used were quite reasonable, (ii) the
prediction performance can later be improved if more
patients’ data become available and (iii) obtaining
miRNA profile (not specific miRNAs) is useful for pre-
dicting the drug response. While current therapy is
based on positive selection with HCV genotype or nega-
tive selection with IL28B SNP, and is limited to only
some cases, our methods are applicable to all patients
[13,18].
Conclusions
Our study shows that the specific miRNA are expressed
differently depending on patient’s drug response. As
result we feel that miRNA profiling can be useful for
predicting patient drug response before the administer-
ing combination therapy thereby reducing ineffective
treatments. Moreover, miRNA expression profile can
facilitate the accumulation of basal information for the
development of novel therapeutic strategies. This
approach allows for more suitable therapeutic strategies
based on clinical information of individuals.
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silico analysis.
Additional file 2: Real-time qPCR validation of immune-related
hypothetical target genes of miRNAs. The expression levels of
hypothetical target genes in HEK293 cells were compared among three
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shown are means+SD of three independent experiments. Asterisk
indicates a significant difference of p < 0.05.
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